Neurosearch denies share manipulation charges
COPENHAGEN (Reuters) - Danish biopharma firm Neurosearch A/S said on Wednesday charges of share price manipulation had been filed against it, but it denied the allegations and said it was working with the authorities to clear up the matter.
Neurosearch said the charges were related to an announcement in February 2010 in which the management of the company reported top-line results from a Phase III study with its Huntington's disease drug candidate Huntexil and then two months later reassessed and corrected the data in a new announcement.
"On the present basis, Neurosearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter," the company said in a statement.
(Reporting by John Acher)
- Tweet this
- Share this
- Digg this
- Supreme Court turns the clock back with gay sex ban
- UPDATE 1-U.S. says Ukraine's "European future" can be saved - Nuland
- CORRECTED-UPDATE 2-India's Supreme Court turns the clock back with gay sex ban
- Google feeds India and China from data centres next door
- Obama and Castro shake hands, Zuma humiliated at Mandela memorial
While focus on the “core” communities has helped keep the disease in check, authorities must “follow the epidemic” and target internal migrants and truckers to widen the scope of prevention efforts, two UNAIDS officials said in an interview with India Insight. Article